The AHA today urged the Centers for Medicare & Medicaid Services to allow a wider variety of documentation to support a critical access hospital’s necessary provider designation, consistent with its past policies. “We are concerned that CMS’s recently articulated requirements around the documentation necessary to support a critical access hospital’s necessary provider designation are inappropriate and unnecessarily limited,” wrote AHA Executive Vice President Tom Nickels. “They may very well have the dire consequence of causing many CAHs to lose the designation that they rightfully obtained prior to 2006. We urge CMS to immediately remedy this issue by revising its requirements to allow alternative methods of documentation.” Interpretive guidance issued by the agency in August lists only one source of evidence that will be considered sufficient – an NP designation letter issued by the state prior to Jan. 1, 2006. “We are extremely concerned that the agency now appears to be creating a retroactive requirement that the states had actually issued such letters, which is not the case in many instances,” AHA said.

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…